These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 24285760)

  • 1. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.
    Tseng A; Szadkowski L; Walmsley S; Salit I; Raboud J
    Ann Pharmacother; 2013 Nov; 47(11):1429-39. PubMed ID: 24285760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older.
    Ranzani A; Oreni L; Agrò M; van den Bogaart L; Milazzo L; Giacomelli A; Cattaneo D; Gervasoni C; Ridolfo AL
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):193-201. PubMed ID: 29767640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
    Halloran MO; Boyle C; Kehoe B; Bagkeris E; Mallon P; Post FA; Vera J; Williams I; Anderson J; Winston A; Sachikonye M; Sabin C; Boffito M
    Antivir Ther; 2019; 24(3):193-201. PubMed ID: 30700636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.
    Holtzman C; Armon C; Tedaldi E; Chmiel JS; Buchacz K; Wood K; Brooks JT;
    J Gen Intern Med; 2013 Oct; 28(10):1302-10. PubMed ID: 23605401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
    Marzolini C; Elzi L; Gibbons S; Weber R; Fux C; Furrer H; Chave JP; Cavassini M; Bernasconi E; Calmy A; Vernazza P; Khoo S; Ledergerber B; Back D; Battegay M;
    Antivir Ther; 2010; 15(3):413-23. PubMed ID: 20516560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Polypharmacy and Potential Drug-Drug Interactions Associated with Risk Factors in the Era of HIV Integrase Inhibitors: A Prospective Clinical Study.
    Altunal LN; Yagcı Caglayık D; Ozel AS; Tukenmez Tigen E; Sili U; Erturk Sengel B; Aydın M; Korten V
    AIDS Patient Care STDS; 2023 Mar; 37(3):138-145. PubMed ID: 36812461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients.
    Krentz HB; Gill MJ
    AIDS Patient Care STDS; 2016 Jan; 30(1):11-7. PubMed ID: 26544766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of prescription medications in home-based older adults with stroke: a pilot study.
    Classen S; Meuleman J; Garvan C; Ried LD; Mann W; Asal N
    Res Social Adm Pharm; 2007 Mar; 3(1):104-22. PubMed ID: 17350560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.
    Okoli C; Schwenk A; Radford M; Myland M; Taylor S; Darley A; Barnes J; Fox A; Grimson F; Reeves I; Munshi S; Croucher A; Boxall N; Benn P; Paice A; van Wyk J; Khoo S
    HIV Med; 2020 Sep; 21(8):471-480. PubMed ID: 32671950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy.
    Yiu P; Nguyen NN; Holodniy M
    Pharmacotherapy; 2011 May; 31(5):480-9. PubMed ID: 21923429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with polypharmacy and the prescription of multiple medications among persons living with HIV (PLWH) compared to non-PLWH.
    Moore HN; Mao L; Oramasionwu CU
    AIDS Care; 2015; 27(12):1443-8. PubMed ID: 26608408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential drug-drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan.
    Kunimoto Y; Matamura R; Ikeda H; Fujii S; Kimyo T; Kitagawa M; Nakata H; Kobune M; Miyamoto A; Fukudo M
    J Pharm Health Care Sci; 2021 Dec; 7(1):43. PubMed ID: 34847955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of comedications and potential drug-drug interactions in people living with HIV in China.
    Chen R; Chen J; Tang Q; Meng Z; Luo L; Zhang W; Deng A; Zhang L; Wang J; Qi T; Zhang R; Shen Y; Liu L; Steinhart C; Lu H
    J Infect Chemother; 2020 Jul; 26(7):722-728. PubMed ID: 32354599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.
    Katende-Kyenda NL; Lubbe MS; Serfontein JH; Truter I
    J Clin Pharm Ther; 2008 Aug; 33(4):393-400. PubMed ID: 18613857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors.
    Deutschmann E; Bucher HC; Jaeckel S; Gibbons S; McAllister K; Scherrer AU; Braun DL; Cavassini M; Hachfeld A; Calmy A; Battegay M; Cipriani M; Elzi L; Young J; Lopez-Centeno B; Berenguer J; Khoo S; Moffa G; Marzolini C;
    Clin Infect Dis; 2021 Oct; 73(7):e2145-e2152. PubMed ID: 32634832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey.
    Igho-Osagie E; Brzozowski K; Jin H; Brown J; Williams MG; Puenpatom A
    Clin Ther; 2023 May; 45(5):390-399.e4. PubMed ID: 37032225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-disease interaction in elderly patients in family practice.
    Mand P; Roth K; Biertz F; Kersting M; Kruschinski C; Schmiemann G; Hummers-Pradier E
    Int J Clin Pharmacol Ther; 2014 May; 52(5):337-45. PubMed ID: 24691059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study.
    López-Centeno B; Badenes-Olmedo C; Mataix-Sanjuan Á; McAllister K; Bellón JM; Gibbons S; Balsalobre P; Pérez-Latorre L; Benedí J; Marzolini C; Aranguren-Oyarzábal A; Khoo S; Calvo-Alcántara MJ; Berenguer J
    Clin Infect Dis; 2020 Jul; 71(2):353-362. PubMed ID: 31428770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.
    Molas E; Luque S; Retamero A; Echeverría-Esnal D; Guelar A; Montero M; Guerri R; Sorli L; Lerma E; Villar J; Knobel H
    HIV Clin Trials; 2018 Feb; 19(1):1-7. PubMed ID: 29179644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.